New Jersey-based Merck & Co. Inc. MRK is a global research-driven pharmaceutical products company. Well known products in Merck’s portfolio include Remicade, Nasonex, Simponi, Vytorin and Zetia, Januvia and Janumet, Isentress, …
Yahoo!2mon
Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. That move followed big gains in the prior few sessions leading up to Wednesday. All told, Merck stock is up more than 10% this year. So what got MRK stock moving higher, …
One thing that does concern me about MRK’s stock at the moment is the large discrepancy between ... It’s rare to find high quality names like this trading at 52-week lows. Like I said before, I think this sell-off is overdone and I plan on …
This week was a relatively light one as far as developments in the pharma sector were concerned. The key highlights were priority review for Merck’s MRK Keytruda for advanced cervical cancer, delay in final data from AstraZeneca’s AZN key …
On Tuesday, Argus reiterated its “buy” rating for MRK stock, and Toung said Lynparza has sweetened the deal. Pharmaceutical giant Merck already has a major growth driver in its Keytruda cancer treatment, and Toung sees even …
Keytruda plus MRK's momentum in hepatitis C treatment may have made the stock a bit too hot last year. This article categorizes and reviews MRK's marketed products from a patent expiration and revenue/growth perspective. Even with …
Shares of Merck & Co. rose on Monday, providing an outsize boost to the Dow Jones Industrial Average in early trading. The stock rose 2.4%, by far the biggest gainer among the blue-chip average's 30 components.
Investors in Merck & Co., Inc. MRK need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 1, 2017 $65 Call had some of the highest implied volatility of all equity options today. Implied …